Fig. 9.
Recovery of CMV-specific T-cell proliferation after donor leukocytes from EBV-seropositive, CMV-seronegative donors for the treatment of an EBV-LPD in UPN 1596, who had concurrent CMV retinitis (upper, 500,000 CD3+ cells/kg), and UPN 1630, who received 100,000 CD3+ T cells/kg for the treatment of persistent CMV viremia despite antiviral therapy (lower).